A paper just published in Nature Biotechnology outlines a pioneering method of screening a person’s diverse set of antibodies for rapid therapeutic discovery. Antibody proteins are an important part of the human immune system that specifically target foreign viruses and bacteria, and they have been the fastest-growing class of approved drugs in the past several decades.
The new techniques made it easier to discover new antibody drug molecules while also learning more about immune responses to vaccines and infections. These advances could lead to better preventions and treatments of diseases like Ebola, HIV, flu and Epstein-Barr virus.
“These technologies are providing a new window on human immune protection that we have never been able to see before,” said co-lead author Brandon DeKosky, assistant professor of chemical & petroleum engineering and pharmaceutical chemistry at the University of Kansas. “They will dramatically accelerate antibody drug development and may also lead to more effective vaccines.”
DeKosky said key innovations set the stage for this new research, including the development of protein display systems in the 1990s, improvements to antibody discovery beginning in the 2000s and the development of technologies to identify natively paired antibody sequences in the 2010s. The new paper combines advances in these three technical areas in an entirely new way to achieve large-scale antibody analysis and screening, resulting in several new and highly potent antibodies in the process.
With co-authors including Bo Wang, Andy Ellington and George Georgiou at the University of Texas-Austin and Morgan Timm, Nancy Sullivan and John Mascola at the National Institutes of Health, DeKosky has developed a technology to screen millions of human B cells to rapidly identify the antiviral antibodies that they contain.
“Antibody molecules are encoded by B cells and are assembled from two different genes, called the heavy and light chains,” the KU researcher said. “The VH and VL portions — derived from the heavy and light chains, respectively — are the sections of an antibody gene that provide specific viral targeting. So, the VH and VL portions are the most important region to focus on for antibody screening and discovery.”
Previous efforts in antibody discovery often relied on single-cell cloning, which led to dozens of experimental or approved drug therapies. However, single-cell cloning holds several major drawbacks because of its very high costs and is limited to sampling a tiny fraction of the human antibody inventory.
“Because antibodies are derived from two different genes — both of which are highly variable and contained within a single B cell — we need to perform single-cell manipulations en masse to recover the set of complete antibody genes,” DeKosky said. “Traditional single-cell cloning is very expensive and time-consuming. The methods described here overcome those limitations and make it possible to screen millions of antibody-producing cells in a single experiment at an academic lab.”
Limitations of previous approaches were a major motivating factor leading to the development of the new technology for screening native antibody libraries.
“Non-natural gene pairing has been used in the past because it’s so much easier to do, but often the quality of antibodies discovered is not good enough for an effective drug, and the synthetic nature of those antibodies makes it difficult to understand the true human immune response,” DeKosky said. “By maintaining native antibody gene pairings throughout our process, we identified antibodies as they occurred naturally. Along the way, we found extremely potent antibodies and learned more about the human immune response to vaccination and natural infection.”
Researchers next will apply this new platform technology to find additional promising antibodies that could serve as the basis for drug therapies.
“Our major motivation was to be able to understand human antibody responses in great detail, which is critical for new therapeutic drug discovery and for vaccine design,” DeKosky said. “Promising sources to discover new antibodies include donated blood samples from HIV patients with powerful immune responses against the virus, and also individuals who have received vaccines so that we can understand how those vaccines are working. When a potently neutralizing antibody is discovered, it can lead to new vaccine strategies and new therapeutic drug candidates.”
Multiple grants and contracts supported the work, including the National Institutes of Health, the intramural research program of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, Leidos Biomedical Research Inc. and the Defense Threat Reduction Agency.
DeKosky said a large number of students and research trainees were involved in this project, including at UT-Austin, NIH and KU.
“This is a prime example of the synergy between academic research and scientific training, where trainees learn by contributing to a larger scientific project,” he said. “This project was several years in the making, and many undergraduates, grad students and postdocs involved have now transitioned to the next stage of their career. Each of us has brought those new skills and ideas along as we transition to different places.”
The KU researcher said these technologies are being applied for drug discovery against a broad range of disease targets in academia, government and the private sector.
“In my lab, we are continuing to develop and improve these systems, and also apply them to learn more about immune responses and discover new therapeutics,” DeKosky said. “We are extremely excited to apply the technology to a host of exciting research problems here at KU — so stay tuned!”
Top right: DeKosky lab members Natalie Bui, undergraduate summer student, and Tiffany Nguyen, post-doctoral researcher, measure DNA in a sample. Credit: Kelly Tong
Bottom right: Student researchers operate the custom equipment for large-scale genetic analysis of single cells. Credit: Kelly Tong
The Latest on: Therapeutic discovery
via Google News
The Latest on: Therapeutic discovery
- Appili Therapeutics Announces Filing of Final Prospectus on June 13, 2019 at 8:40 am
HALIFAX, Nova Scotia--(Business Wire)--Biopharmaceutical company Appili Therapeutics Inc. ("Appili" or the "Company ... ATI-1503 is a drug discovery program aimed at generating negamycin analogue ... […]
- BlackThorn Therapeutics Closes $76 Million Series B to AdvanceTargeted Therapeutics for Mental Health on June 13, 2019 at 5:30 am
BlackThorn Therapeutics, a clinical-stage ... to inform rational, targeted drug discovery and development.” “BlackThorn was founded to bring new therapies to patients by applying advances in ... […]
- G1 Therapeutics Announces Updates to Board of Directors on June 13, 2019 at 5:01 am
About G1 Therapeutics G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those ... […]
- Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership on June 13, 2019 at 4:30 am
Jill Weimer, PhD named Senior Vice President of Discovery Research and Gene Therapy ... 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced two new additions to the Senior ... […]
- Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation on June 13, 2019 at 4:00 am
SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development ... […]
- AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease on June 13, 2019 at 3:46 am
AbCellera, a leader in therapeutic antibody discovery from natural immune systems, today announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic ... […]
- Seventure Partners invests in Domain Therapeutics on May 28, 2019 at 4:16 am
Domain Therapeutics said May 28 that it secured a 3.5 million euros ($3.9 million) investment from existing shareholder Seventure Partners. Domain is a French biopharma company that is involved in the ... […]
- Office Bridges Gap Between Discovery, Therapeutics on May 21, 2019 at 12:54 pm
A department at UC San Diego Health’s Moores Cancer Center is known for putting on a symposium to translate groundbreaking oncology discoveries into therapeutics. The annual event generates a good ... […]
- Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration on May 21, 2019 at 1:55 am
Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ZoBio, the leading contract research organization in integrated fragment-based drug ... […]
via Bing News